| Benicar HCT Dosages & Strengths | ||||
|---|---|---|---|---|
| Strength | Format | Route | Strength | Class |
| Benicar HCT 25 mg-40 mg | tablet | oral | 1.0 each | OTC |
| Benicar HCT 12.5 mg-20 mg | tablet | oral | 1.0 each | OTC |
| Benicar HCT 25 mg-40 mg | tablet | oral | 1.0 each | OTC |
| Benicar HCT 12.5 mg-20 mg | tablet | oral | 1.0 each | OTC |
Posted by maryjones about 1 year ago
No side effects yet.
Microbia and Forest Laboratories Announce Preliminary Results of ... - PharmaLive.com (press release)
*Azor is a trademark of Daiichi Sankyo, Inc.; Benicar and Benicar HCT are registered trademarks of Daiichi Sankyo, Inc.; and Campral is a registered ...
Wed Mar 05 08:50:48 -0500 2008
Author : Microbia, Inc. and Forest Laboratories, Inc. - Earthtimes
*Azor is a trademark of Daiichi Sankyo, Inc.; Benicar and Benicar HCT are registered trademarks of Daiichi Sankyo, Inc.; and Campral is a registered ...
Tue Mar 04 18:07:27 -0500 2008
Forest Laboratories, Inc. Announces Amendment to Bystolic(TM ... - FOXBusiness
Azor is a trademark of Daiichi Sankyo, Inc.; Benicar and Benicar HCT are registered trademarks of Daiichi Sankyo, Inc.; and Campral is a registered ...
Thu Feb 28 06:12:51 -0500 2008
hydrochlorothiazide - The hydrogenated derivative of chlorothiazide, a thiazide diuretic with antihypertensive and anti-urolithic effects. This agent binds to the electroneutral Na-K-Cl cotransporter (NKCC) and thereby impairs Na+, K+ and Cl- reabsorption on the luminal membrane of the early segment in the distal convoluted tubule in the kidney. This leads to an increase in urinary excretion of sodium, chloride, potassium, bicarbonate and water subsequently reducing plasma and extracellular fluid volume leading to a reduction in blood pressure. Hydrochlorothiazide also decreases urinary calcium and uric acid excretion by direct action on the distal tubule.
olmesartan medoxomil - A synthetic imidazole derivative prodrug with an antihypertensive property. Upon hydrolysis, olmesartan medoxomil is converted to olmesartan. Olmesartan selectively binds to the angiotensin type 1 (AT1) receptor of angiotensin II in vascular smooth muscle and adrenal gland, thereby competing angiotensin II binding to the receptor. This prevents angiotensin II-induced vasoconstriction and decreases aldosterone production, thereby preventing aldosterone-stimulated sodium retention and potassium excretion.